Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Naloxone shortage

Executive Summary

FDA contracts Canadian company Sabex to supply morphine antagonist pending shortage resolution. Narcan manufacturer Endo had experienced manufacturing difficulties due to DuPont plant shutdown (1"The Pink Sheet" March 26, In Brief). According to the American Society of Health-System Pharmacists, Endo plans to release back orders by early June, while Abbott expects releases in April and May. Sabex' naloxone will not be available for intrathecal use

You may also be interested in...



FDA Drug Shortage Role Should Focus On Prevention, GPOs Suggest

The Health Industry Group Purchasing Association is proposing that FDA offer a "safe haven" for manufacturers to discuss potential product discontinuations or supply disruptions

FDA Drug Shortage Role Should Focus On Prevention, GPOs Suggest

The Health Industry Group Purchasing Association is proposing that FDA offer a "safe haven" for manufacturers to discuss potential product discontinuations or supply disruptions

Endo Narcan

Shortages of naloxone are due to shutdown of DuPont sterile manufacturing facility, Endo explains (1"The Pink Sheet" March 19, p. 16). DuPont says manufacturing facility was closed for routine repair and maintenance. Endo expects production to be resumed by the end of March. DuPont's Manati, Puerto Rico facility received a warning letter in June 2000 for deviations from good manufacturing practices

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel